Monthly methylprednisolone in combination with interferon beta or glatiramer acetate for relapsing-remitting multiple sclerosis: a multicentre, single-blind, prospective trial
Multiple sclerosis (MS) is a chronic immune-mediate disease involving both genetic and environmental determinants. It is usually clinically characterized by repeated subacute relapses followed by remissions, known as relapsing –remitting MS (RRMS). No curative treatment for MS is available, and therapeutic strategies are aimed at treating relapses, preventing new relapses and avoiding progression of disability [1]. Treatment of relapses has been based on the use of corticosteroids since the early 1950s.
Source: Clinical Neurology and Neurosurgery - Category: Neurosurgery Authors: Serkan Ozakbas, Bilge Piri Cinar, Gorkem Kosehasano ğullari, Turhan Kahraman, Didem Oz, Behice Bircan Kursun Source Type: research
More News: Brain | Copaxone | Corticosteroid Therapy | Disability | Environmental Health | Eyes | Genetics | Methylprednisolone | Multiple Sclerosis | Neurology | Neurosurgery